Haydarpasa Numune Med J. 2021; 61(2): 197-203 | DOI: 10.14744/hnhj.2019.20438

Comparison of Rifaximin and Trimebutin Maleate Treatment for Irritable Bowel Syndrome with Constipation and Diarrhea

Bilge Örmeci Baþ
Department of Gastroenterology, Antalya Training and Research Hospital, Antalya, Turkey

INTRODUCTION: Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with changes in bowel habits, abdominal pain, and gas without any organic pathology. IBS is divided into three types as constipation – IBS (IBS-C), diarrhea – IBS (IBS-D), and mixed. Rifaximin is an antibiotic that improves IBS symptoms by improving the flora in the intestine. The aim of the study was to determine whether the treatment of rifaximin is superior to treatment.
METHODS: This study performed retrospectively and patients were divided into two groups as IBS-C and IBS-D. Each group was divided into two groups as rifaximin and Trimebutin Maleate treatment. Rifaximin at a dose of 200 mg, 3×2 daily for 15 days. Trimebutin Maleate group includes lifestyle modification and Trimebutin Maleate 200 mg 3×1. At the end of the treatment and after 20 days, the patients were re-evaluated.
RESULTS: A total of 179 subjects had examined. In terms of IBS symptoms; bloating, abdominal pain, and stool consistency, both treatments are effective as long as patients continue treatment; however, 20 days after the end of the treatment, rifaximin treatment was found to be more effective than trimebutin maleate treatment.
DISCUSSION AND CONCLUSION: The use of rifaximin provides significant long-term improvement in both diarrhea and constipation IBS patients compared to Trimebutin Maleate treatment.

Keywords: Constipation, diarrhea, irritable bowel syndrome; rifaximin; trimebutine maleate.

---

Konstipasyon ve Diare Baskýn Ýrritabl Baðýrsak Sendromu için Rifaximin ve Trimebutin Maleat Tedavisinin Karþýlaþtýrýlmasý

Bilge Örmeci Baþ
Antalya Eðitim ve Araþtýrma Hastanesi, Gastroenteroloji Bölümü, Antalya, Türkiye

GÝRÝÞ ve AMAÇ: GÝRÝÞ ve AMAÇ: Ýrritabl baðýrsak sendromu (ÝBS), altýnda organik patoloji olmadan karýn aðrýsý, gaz ve baðýrsak alýþkanlýklarýnda deðiþiklikle karakterize fonksiyonel bir gastrointestinal hastalýktýr. Kabýzlýk baskýn, ishal baskýn ve karýþýk olmak üzere üç türe ayrýlýr. Rifaximin, baðýrsaktaki florayý etkileyerek ÝBS semptomlarýný iyileþtirebileceði düþünülen bir antibiyotiktir. Bu çalýþmada amaç Rifaximin tedavisinin diare ve konstipasyon aðýrlýklý ÝBS hastalarýnda Trimebutin Maleat tedavisine üstün olup olmadýðýný göstermektir.
YÖNTEM ve GEREÇLER: Bu retrospektif çalýþmada hastalar konstipasyon ve diare aðýrlýklý ÝBS olarak iki grupta incelendi. Ayrýca her bir grup Trimebutin Maleat ve rifaximin tedavisi olarak alt gruplara ayrýldý. Rifaximin grubuna ilaç 200 mg, 3x2, 15 gün süreyle verildi. Trimebutin Maleat grubunda yaþam tarzý deðiþiklikleri ve Trimebutin Maleat 200 mg 3x1 verildi. Tedavi bitiminde ve 20 gün sonra hastalar tekrar deðerlendirildi.
BULGULAR: Toplam 179 hasta incelendi. ÝBS semptomlarý; þiþkinlik, karýn aðrýsý, dýþký þekli; açýsýndan bakýldýðýnda tedavi süresünce her iki tedavinin etkin olduðu ancak tedavi bitiminden 20 gün sonra Rifaximin tedavisinin Trimebutin Maleat tedavisine kýyasla daha etkin olduðu görüldü.
TARTIÞMA ve SONUÇ: Rifaximin kullanýmý hem diare hem de konstipasyon aðýrlýklý ÝBS hastalarýnda Trimebutin Maleat tedavisine göre uzun dönemde anlamlý düzelme saðlamaktadýr.

Anahtar Kelimeler: Diare, irritabl baðýrsak sendromu, konstipasyon, Rifaximin, Trimebutin Maleat

---

CITE